Recombinant B Lymphocyte Cell Line for Dual Antigen Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing immunoglobulins in B lymphocyte cell lines are limited in their ability to simultaneously express membrane and secreted immunoglobulins with different antigen specificities, which hampers the development of effective immunotherapeutic products for treating diseases.
Innovation Solution
A recombinant B lymphocyte cell line is engineered to express exogenously incorporated membrane immunoglobulins reactive to one antigen and endogenously or exogenously derived secreted immunoglobulins reactive to a different antigen, allowing for the production of both membrane-bound and secreted antibodies with distinct antigen specificities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If B lymphocyte cell lines are engineered to express membrane immunoglobulins with specific antigen reactivity, then the ability to produce targeted antibodies is improved, but the complexity of simultaneously expressing multiple immunoglobulin types with different specificities increases
Solution Approach 1:
The patent divides the immunoglobulin expression system into separate functional components: membrane immunoglobulins for antigen recognition and presentation, and secreted immunoglobulins for antibody production. By segmenting the expression functions and using independent nucleic acid constructs for each type, the system achieves multiple antigen specificities without overwhelming complexity
Solution Approach 2:
The recombinant B lymphocyte cell line is engineered to perform multiple functions simultaneously: it expresses membrane immunoglobulins for antigen binding and presentation, while also producing secreted immunoglobulins for humoral immunity. This multi-functional cell line design allows a single cell type to address multiple immune responses against different antigens
2Productivity
If multiple nucleic acids are incorporated into B lymphocyte cell lines to express different immunoglobulins, then the productivity of immunotherapeutic products is improved, but the difficulty of controlling expression and ensuring stability increases
Solution Approach 1:
The patent applies local quality by assigning different functional roles to different nucleic acid components within the same cell line. Membrane immunoglobulin nucleic acids are configured for stable integration and long-term expression, while secreted immunoglobulin nucleic acids are optimized for high-level production. Each nucleic acid construct has tailored regulatory elements and structural features suited to its specific function, ensuring both productivity and stability
3Adaptability or versatility
If recombinant B lymphocyte cell lines produce both membrane and secreted immunoglobulins with different antigen specificities, then the versatility of immunotherapeutic applications is improved, but the manufacturing process complexity increases
Solution Approach 1:
The patent merges the production of membrane and secreted immunoglobulins with different antigen specificities into a single recombinant B lymphocyte cell line system. By combining multiple nucleic acid constructs encoding different immunoglobulin types within one cell line, the manufacturing process is simplified compared to producing and pooling products from multiple separate cell lines, while still achieving versatile therapeutic applications
Data Source
AI summary
Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen.